An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for broader availability to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how regulators view custom-mixed peptide therapies, which have drawn increasing interest from consumers seeking alternatives to standard drugs. Researchers say peptide treatments could change approaches to stubborn infections, though concerns about quality persist. The committee's endorsement of four peptides clears a path for more broad prescribing, even as watchdogs warn of limited evidence. Industry analysts note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on particular peptide candidates.